Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) and Bausch Health Cos (NYSE:BHC – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation and institutional ownership.
Profitability
This table compares Taysha Gene Therapies and Bausch Health Cos’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Taysha Gene Therapies | -1,201.08% | -104.93% | -50.09% |
| Bausch Health Cos | -0.41% | -540.45% | 5.26% |
Analyst Ratings
This is a summary of recent ratings and target prices for Taysha Gene Therapies and Bausch Health Cos, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Taysha Gene Therapies | 0 | 0 | 6 | 0 | 3.00 |
| Bausch Health Cos | 1 | 6 | 0 | 0 | 1.86 |
Institutional & Insider Ownership
77.7% of Taysha Gene Therapies shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 3.8% of Taysha Gene Therapies shares are held by insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Taysha Gene Therapies and Bausch Health Cos”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Taysha Gene Therapies | $8.33 million | 60.69 | -$89.30 million | ($0.34) | -6.93 |
| Bausch Health Cos | $9.73 billion | 0.26 | -$46.00 million | ($0.11) | -61.86 |
Bausch Health Cos has higher revenue and earnings than Taysha Gene Therapies. Bausch Health Cos is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Taysha Gene Therapies has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.28, indicating that its share price is 72% less volatile than the S&P 500.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
About Bausch Health Cos
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
